Taiho Pharmaceutical Acquires Cullinan Pearl to Co-develop CLN-081/TAS6417

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

TenX Keane Acquisition Merges with Citius Pharmaceuticals' Oncology Subsidiary to Form Citius Oncology, Inc.

August 12, 2024

Biotechnology

TenX Keane Acquisition (Nasdaq: TENK) completed a merger with Citius Pharmaceuticals' wholly owned oncology subsidiary to form the publicly traded Citius Oncology, Inc. Citius Pharmaceuticals retains approximately 90% ownership of the new company, which will commercialize the recently FDA-approved oncology therapy LYMPHIR and trade on Nasdaq under the ticker CTOR.

Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

February 7, 2025

Pharmaceuticals

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out from Mitsubishi Chemical Group Corporation for approximately 510 billion JPY (about $3.3 billion). The deal, led by Bain’s Private Equity teams in Asia and North America together with its Life Sciences group, will create an independent, standalone Japanese pharma platform focused on drug discovery and development across immunology, CNS, vaccines, diabetes and other priority areas; the transaction is expected to close in Q3 2025.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Aterian Investment Partners Acquires Contract Pharmaceuticals Limited

June 6, 2024

Pharmaceuticals

Aterian Investment Partners, through an affiliate, has acquired Contract Pharmaceuticals Limited (CPL), a Mississauga-based CDMO specializing in non-sterile liquid and semi-solid pharmaceutical and OTC products. Aterian said it will invest in people, technology and processes to support CPL's next phase of growth and further strengthen its position serving global pharmaceutical customers.